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Death by effectiveness: exercise as
medicine caught in the efﬁcacy trap!
Chris Beedie,1,2 Steven Mann,2 Alfonso Jimenez,2,3 Lynne Kennedy,2,4
Andrew M Lane,5 Sarah Domone,2 Stephen Wilson,2 Greg Whyte2,6
Sport and Exercise Medicine (SEM) has
had a good run. For a while it was the
low-cost magic bullet. With efﬁcacy
demonstrated in study after study, the con-
clusion was clear: ‘Exercise is Medicine’, a
potential public health panacea.
Sadly, the early promise waned. While
we continue to be bombarded by original
research and reviews extoling the efﬁcacy
of exercise, there is an apparent dearth of
evidence of its effectiveness. This fact is
highlighted in 2014 reports from the UK
Government1 and Public Health England.2
It is often argued that the major chal-
lenge to the effectiveness of exercise is
adherence. Adherence to exercise, vari-
ously reported at between 40% and 50%3
is no lower than that reported for drugs.4
However, while there is general conﬁ-
dence that licensed drugs are effective
when taken, reports cited above1 2 suggest
that this conﬁdence does not currently
extend to exercise.
Conﬁdence in drugs results from their
demonstrating efﬁcacy and effectiveness in
clinical trials. Efﬁcacy, demonstrated in
phases I–III of a trial, refers to “the extent
to which a drug has the ability to bring
about its intended effect under ideal cir-
cumstances”.5 Effectiveness, demonstrated
in phase IV studies, refers to “the extent to
which a drug achieves its intended effect in
the usual clinical setting”.5 Effectiveness
is what matters to commissioners and
patients.
The requirement for effectiveness (ie,
phase IV) studies is well recognised.6 A sub-
stantial volume of social science research
has examined real-world exercise interven-
tions and therefore constitutes phase IV
research. However, all too often resultant
data relate largely or exclusively to exercise
behaviour, providing evidence of
behavioural or implementation effectiveness
but little evidence of clinical or treatment
effectiveness.7 In all exercise interventions,
exercise behaviour is the throughput, with
health status the output. Outputs are more
important to stakeholders.
Furthermore, a recent review8 identiﬁed
that many studies examining the treatment
effectiveness of exercise in the real world
adopt laboratory style methods and con-
trols that would be impractical and uneco-
nomic in real-world interventions. Data
resulting from such studies merely add to
the efﬁcacy data set.
We argue that despite metaphorically
drowning in evidence of efﬁcacy and
implementation effectiveness, SEM is yet
to provide sufﬁcient evidence of treatment
effectiveness. Furthermore, while it is a
mistake to confuse efﬁcacy with effective-
ness,9 in lobbying for exercise as a public
health tool, we often do just that.
On the basis of the above we believe
that SEM risks being side-lined in public
health. If we are to provide critical life
support to SEM—and arguably to belea-
guered health services—that lifeline is the
production of high-quality phase IV/
effectiveness research.
A phase IV methodology applicable to a
wide range of exercise interventions is the
large simple trial (LST).10 LSTs are embed-
ded in the delivery of treatment, make use
of existing data and service infrastructure,
demand little extra effort of practitioners
and patients, and can be conducted at
relatively modest costs (this factor being
critical at a time when commissioners legit-
imately question the allocation to research
of funds better spent on care).10 While a
randomised controlled trial maximises val-
idity but has limited generalisability, and
an observational study has limited validity
but maximises generalisability, a well-
conducted LST maximises validity and
generalisability.10 In fact, LSTs represent a
combination of a process evaluation,
important to stakeholders, and a research
study, important to science (perhaps ‘con-
trolled evaluation’ would in fact be an
appropriate alternative descriptor).
No matter how efﬁcacious an interven-
tion during phases I–III of a clinical trial,
if patients do not take it, or it does not
demonstrate its effectiveness among those
who do, it should not be commissioned.
If the SEM community fails to provide
evidence for the effectiveness of exercise,
we could condemn subsequent genera-
tions of the population to increasingly
complex and expensive biomedical inter-
ventions, with the associated likelihoods
of poorer public health and greater health
inequalities. We might also condemn our
discipline to the status of a side show to
the main event.
The ‘SEM community’ extends to journal
editors, commissioners, practitioners and
representative bodies, all of whom have a
part to play. Journal editors must recognise
the value of real-world research, and accept
that it cannot meet the rigorous methodo-
logical standards of laboratory work. Public
health commissioners should not only insist
on evidence-based practice, but should insist
that ongoing data capture is a feature of all
commissioned interventions. Accordingly,
practitioners and providers must become
adept at embedding data capture and ana-
lysis into all relevant activity. Representative
bodies must lobby government, health agen-
cies and research councils to provide greater
funding for effectiveness research.
However, while the contributions above
are important, it is SEM researchers who
must play the leading role. A commitment
to conducting rigorous effectiveness
studies might be critical if SEM is to avoid
the inexorable decline into an early grave!
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